NASDAQ:IART
Integra Lifesciences Holdings Corp.
Integra Lifesciences Holdings Corp.'s revenue grew 1.5% in fiscal 2025 to $1.6B while operating margin fell to −30.2%, its lowest in 10 years. Free cash flow was −$31.1M, −1.9% of revenue.Summary generated from Integra Lifesciences Holdings Corp.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.6B
Revenue growth+1.5%
Revenue, 5-yr CAGR+3.6%
Gross margin50.9%
Operating margin−30.2%
Net margin−31.6%
ROIC−21.7%
Return on equity−39.9%
Debt / equity0.70
Free cash flow−$31.1M
FCF margin−1.9%
Share count change−0.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1,542 | 1,558 | 1,542 | 1,611 | 1,635 |
| Operating income | 197 | 239 | 112 | 28 | −493 |
| Net income | 169 | 181 | 68 | −7 | −516 |
| Free cash flow | 264 | 222 | 73 | 25 | −31 |
Recent filings
- 8-KRegulation FD disclosure
Oct 9, 2026 - 8-KResults of operations and financial condition
Oct 2, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 4Insider transaction report
Sep 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 4Insider transaction report
Jul 6, 2026 - 8-KDirector or officer change
May 8, 2026